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Abstract
Background: Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic tropical disease. It
progresses from the first, haemolymphatic stage to a neurological second stage due to invasion of parasites into the central
nervous system (CNS). As treatment depends on the stage of disease, there is a critical need for tools that efficiently
discriminate the two stages of HAT. We hypothesized that markers of brain damage discovered by proteomic strategies and
inflammation-related proteins could individually or in combination indicate the CNS invasion by the parasite.
Methods: Cerebrospinal fluid (CSF) originated from parasitologically confirmed Trypanosoma brucei gambiense patients.
Patients were staged on the basis of CSF white blood cell (WBC) count and presence of parasites in CSF. One hundred
samples were analysed: 21 from stage 1 (no trypanosomes in CSF and #5 WBC/mL) and 79 from stage 2 (trypanosomes in
CSF and/or .5 WBC/mL) patients. The concentration of H-FABP, GSTP-1 and S100b in CSF was measured by ELISA. The levels
of thirteen inflammation-related proteins (IL-1ra, IL-1b, IL-6, IL-9, IL-10, G-CSF, VEGF, IFN-c, TNF-a, CCL2, CCL4, CXCL8 and
CXCL10) were determined by bead suspension arrays.
Results: CXCL10 most accurately distinguished stage 1 and stage 2 patients, with a sensitivity of 84% and specificity of
100%. Rule Induction Like (RIL) analysis defined a panel characterized by CXCL10, CXCL8 and H-FABP that improved the
detection of stage 2 patients to 97% sensitivity and 100% specificity.
Conclusion: This study highlights the value of CXCL10 as a single biomarker for staging T. b. gambiense-infected HAT
patients. Further combination of CXCL10 with H-FABP and CXCL8 results in a panel that efficiently rules in stage 2 HAT
patients. As these molecules could potentially be markers of other CNS infections and disorders, these results should be
validated in a larger multi-centric cohort including other inflammatory diseases such as cerebral malaria and active
tuberculosis.
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Introduction
Human African trypanosomiasis (HAT), also called sleeping
sickness, is a parasitic disease that occurs in sub-Saharan Africa.
More than sixty million people are at risk of being infected. The
World Health Organization (WHO) has reported impressive
progress since 1995 in the control of HAT, leading to a substantial
reduction of new cases detected yearly to 10’800 in 2007. The total
number of cases is now estimated to be between 50’000 and
70’000 per year [1].
The parasite that causes HAT belongs to the Trypanosoma brucei
family with two subspecies, Trypanosoma brucei gambiense and
Trypanosoma brucei rhodesiense, responsible for the human disease.
Trypanosomes are transmitted to humans by the bite of a tsetse fly
and are initially confined to the blood, lymph nodes and
peripheral tissues. This corresponds to the first stage (early stage;
or haemolymphatic stage) of the disease. After an unknown period
that varies from weeks to months, the parasites invade the central
nervous system (CNS). This is called the second stage (late stage; or
neurologic; or meningo-encephalitic stage) of HAT.
Clinical symptoms of HAT are not specific for the disease, and
definite diagnosis is always based on parasitological examination of
body fluids. The card agglutination test for trypanosomiasis
(CATT), an assay that is based on trypanosome-specific antibody
detection, is widely used for mass screening. However, it suffers
from limited sensitivity and restricted to the T. b. gambiense form of
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followed by stage determination, which is performed by exami-
nation of the cerebrospinal fluid (CSF). This is a vital step in the
diagnostic process, as the treatment differs depending on the stage
of the disease. If HAT patients are not treated, they always die [3–
5]. Early stage drugs are inefficient for late stage patients, and
additionally, melarsoprol (MelB or Arsobal), which has been the
most widely used drug to treat late stage patient, has itself an
overall mortality rate of 5% due to its toxicity [6]. As a
consequence, melarsoprol has in many countries been replaced
by eflornithine as the first line treatment for T. b. gambiense
infections but the latter drug suffers from important logistic
constraints.
WHO defined late-stage HAT by the following criteria:
presence of trypanosomes in CSF and/or an elevated WBC count
above 5/mL of CSF [7]. However, presence of WBC in the CSF is
not specific for the disease and parasite detection methods are not
sensitive enough [8]. Furthermore, recent studies suggest the need
to increase the cutoff between the first and second stages to 10 or
20 WBC/mL [2,8,9]. This has contributed to the concept of a
potential intermediate stage of HAT with CSF WBC count .5
and #20 WBC/mL [10]. There is therefore a critical need for a
reliable and efficient staging tool that would replace or
complement trypanosome detection and WBC count.
Parasite migration and invasion of the CNS causes a
neuroinflammatory process, associated with activation of microg-
lial cells and astrocytes [11,12], and infiltration of the CNS with
leukocytes (predominantly mononuclear cells) [13]. Cytokines and
chemokines are known to be actively involved in this process.
Thus, TNF-a, IL-6, CXCL8 and IL-10 concentrations have been
demonstrated to be elevated in the CSF of late-stage patients
[11,14] and the IFN-c level has been reported as associated with
the severity of the late stage disease [15]. The levels of CCL2, IL-
1b and CXCL8 have also been correlated with presence of
parasites in the CSF and neurological signs in HAT patients [16].
Additionally, levels of IL-1ra, G-CSF, VEGF, CCL4 and
CXCL10 were found modulated in either the CSF or plasma of
patients suffering from cerebral malaria [17–19], and could
potentially be also modulated in HAT patients.
Proteomic analysis of human body fluids has become an
important approach for biomarkers discovery [20]. In this context,
we recently explored the concept of post-mortem CSF as a model of
massive and global brain insult [21], which allowed the
identification of potential brain damage biomarkers by proteomics
strategies. Indeed, heart-fatty acid binding protein (H-FABP),
identified from post-mortem CSF, has been validated as a marker of
stroke [22] and Creutzfeldt-Jakob disease [23], respectively.
Similarly, GSTP-1 was also found over-expressed in post-mortem
CSF [24] compared to ante-mortem, and was recently validated as
an early diagnostic marker of stroke and traumatic brain injury
(Turck et al. Personal communication). Additionally, S100b
protein has already been demonstrated to be a marker of blood-
brain barrier (BBB) and neuronal damage [25] as well as a useful
serum biomarker of CNS injury and a potential tool for predicting
clinical outcome after brain damage [26].
In this context, we hypothesized that markers of brain damage
discovered by proteomic strategies as well as inflammation-related
proteins could individually or in combination indicate the CNS
invasion by the trypanosome parasite. We measured the CSF
concentrations of H-FABP, GSTP-1, S100b and thirteen inflam-
mation-related proteins (IL-1ra, IL-1b, IL-6, IL-9, IL-10, G-CSF,
VEGF, IFN-c, TNF-a, CCL2, CCL4, CXCL8 and CXCL10) and
evaluated their potential for staging the disease.
Material and Methods
Samples
Samples originated from a prospective observational study on
shortening of post treatment follow-up in gambiense human African
trypanosomiasis (THARSAT), conducted between 2005 and 2008
at Dipumba hospital in Mbuji-Mayi (Kasai Oriental province,
Democratic Republic of the Congo). Details of the THARSAT
study design and results are reported elsewhere (D. Mumba Ngoyi,
in preparation). The study protocol was approved by the Ministry
of Health, Kinshasa, DRC and by the Ethical Committee of the
University of Antwerp, Belgium. Briefly, 360 T. b. gambiense
patients in total were enrolled into the THARSAT study.
Inclusion criteria were 1u confirmed presence of trypanosomes
in lymph nodes, blood or CSF; 2u$12 years old and; 3u living
within a perimeter of 100 km around Mbuji-Mayi. Exclusion
criteria were 1u pregnancy; 2u no guarantee for follow-up; 3u
moribund; 4u haemorrhagic CSF before treatment and; 5u
presence of another serious illness (active tuberculosis - treated
or not, bacterial or cryptococcal meningitis). HIV and malaria
were not considered as exclusion criteria. Each patient underwent
a clinical examination. Staging of disease was based on CSF
examination. WBC count was performed in disposable cell
counting chambers (Uriglass, Menarini) and was performed in
duplicate when the first count was ,20 cells/mL. Trypanosomes
were searched for in CSF by direct examination prior or during
the cell counting procedure, followed by the modified single
centrifugation method [27]. Second stage patients were defined as
having .5 WBC/mL and/or trypanosomes in the CSF. First stage
patients were defined as having 0–5 WBC/mL and no trypano-
somes in the CSF. Patients having .5 and #20 WBC/mL and no
trypanosomes in CSF were defined and treated as stage 2 patients,
but highlighted as being in the potential intermediate stage.
Patients or their responsible were informed about the study
objectives and modalities and were asked to provide written
consent. Treatment was provided according to the guidelines of
the national control program for HAT (PNLTHA).
CSF samples were centrifuged immediately after collection. The
supernatant remaining after the diagnostic procedure was
Author Summary
The actual serological and parasitological tests used for the
diagnosis of human African trypanosomiasis (HAT), also
known as sleeping sickness, are not sensitive and specific
enough. The card agglutination test for trypanosomiasis
(CATT) assay, widely used for the diagnosis, is restricted to
the gambiense form of the disease, and parasitological
detection in the blood and cerebrospinal fluid (CSF) is
often very difficult. Another very important problem is the
difficulty of staging the disease, a crucial step in the
decision of the treatment to be given. While eflornithine is
difficult to administer, melarsoprol is highly toxic with
incidences of reactive encephalopathy as high as 20%.
Staging, which could be diagnosed as early (stage 1) or
late (stage 2), relies on the examination of CSF for the
presence of parasite and/or white blood cell (WBC)
counting. However, the parasite is rarely found in CSF
and WBC count is not standardised (cutoff set between 5
and 20 WBC per mL). In the present study, we hypothesized
that an early detection of stage 2 patients with one or
several proteins in association with clinical evaluation and
WBC count would improve staging accuracy and allow
more appropriate therapeutic interventions.
Biomarkers for Staging HAT
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study reported here, a total of 100 CSF samples, taken before
treatment, were tested. These samples originated from 21 stage 1
(S1) and 79 stage 2 patients (S2). S1 patients were age and sex
matched with 21 S2 patients. Remainder S2 patients were chosen
in order to obtain homogenous median age values. Patients were
classified into three categories of neurological signs; absent (no
neurological signs), moderate (at least one major neurological sign
but no generalised tremors) or severe (at least two major
neurological signs including generalised tremors). Major neuro-
logical signs were defined as: daytime somnolence, sensory and
gait disturbances, presence of primitive reflexes (Babinski’s sign,
palmo-mental reflex, perioral reflex), modified tendon reflexes
(exaggeration or abolition), abnormal movements such as tremor
(fine, diffuse and generalised). Neurological signs were not
reported for two patients.
S100b, H-FABP and GSTP-1 measurements
The concentration of S100b was measured using a commer-
cially available sandwich ELISA assay kit (Abnova, Taiwan)
following the manufacturer’s instructions. Briefly, calibrators,
Quality control (QC) and CSF samples diluted 1:4 were incubated
2 hours on microtiter strips pre-coated with polyclonal anti-cow
S100b antibodies. After 3 washes, horseradish peroxidase (HRP)
labelled anti-human S100b antibodies were added, incubated for
90 minutes and washed again before addition of the substrate
solution (tetramethylbenzidine). Color development was stopped
with sulphuric acid and absorbance was read on a Vmax Kinetic
microplate reader, (Molecular Devices Corporation, Sunnyvale,
CA, U.S.A.) at a wavelength of 450 nm.
H-FABP concentration was also determined using a commer-
cially available ELISA kit (Hycult Biotechnology, Uden, Nether-
lands) according to the manufacturer’s instructions. CSF samples
(non-diluted) and standards were incubated (1 hour) together with
peroxidase conjugated secondary antibodies in microtiter wells
coated with antibodies recognizing human H-FABP. After 3
washes, tetramethylbenzidine was added and color development
was stopped by adding citric acid.
The concentration of GSTP-1 was determined using a
homemade ELISA as described by Allard et al. [28]. Briefly,
biotinylated anti-GSTP-1 antibodies (2 mg/mL) (Biosite, Califor-
nia, USA) were coated onto a 96-well Reacti-Bind NeutrAvidin
coated Black Plates (Pierce, Rockford, IL) for 1 hour at 37uC.
After 3 washes, CSF samples (diluted 1:4), quality controls and
standards (recombinant GSTP-1 at concentrations ranging from 0
to 100 ng/mL) were incubated for 1 hour at 37uC, and followed
by a washing step. Alkaline phosphatase conjugated antibodies
against human GSTP-1 (Biosite, California, USA) at 2 mg/mL
were added and incubated for 1 hour at 37uC. After 3 washes,
Attophos AP fluorescent substrate (Promega, Madison, WI) was
added and plates were read immediately on a SpectraMax
GEMINI-XS (Molecular Devices Corporation, Sunnyvale, CA,
U.S.A.) plate reader, using the kinetic mode. Vmax values were
automatically calculated by the instruments based on relative
fluorescence units (RFU) (lexcitation=444 nm and lemission
=555 nm).
Concentrations of S100b, H-FABP and GSTP-1 in the CSF
samples were back-calculated using a linear calibration curve
based on measured standards values.
Bead suspension array
The levels of thirteen cytokines and chemokines (IL-1ra, IL-1b,
IL-6, IL-9, IL-10, G-CSF, VEGF, IFN-c, TNF-a, CCL2, CCL4,
CXCL8 and CXCL10) were determined using the Bioplex bead
suspension arrays according to the manufacturer’s instructions (Bio-
Rad, Hercules, CA). Briefly, thirteen sets of color-coded polystyrene
beads were conjugated separately with one of the thirteen different
antibodies against the molecule of interest. All the sets were then
mixed together by the supplier and delivered ready-to-use. An equal
amount of beads was added to each well of a 96-well filter plate.
After a series of washes, standards and samples (diluted 1:4) were
added and incubated for 30 minutes at room temperature. After
washing, a mix of the corresponding thirteen biotinylated detection
antibodies was added and incubated 30 minutes at room temper-
ature. After washing, streptavidin-phycoerythrin (streptavidin-PE)
was added for 10 minutes. After a last series of washes, beads were
re-suspended in the provided assay buffer and each well was
aspirated using the Bio-Plex system. Each bead was identified and
the corresponding target simultaneously quantified based respec-
tively on bead color and fluorescence. The concentration of each
target was automatically calculated by the Bio-Plex Manager
software using corresponding standard curve (5-PL regression)
obtained from recombinant protein standards.
Data and statistical analysis
Descriptive statistics were performed using the SPSS (version
16.0, SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version
4.03, GraphPad software Inc., San Diego, CA, USA) software.
Because none of the markers presented a normal distribution in
concentrations (Kolmogorov-Smirnov test), differences between
groups were tested with non-parametric Mann-Whitney U test
(comparison between two groups) and Kruskal-Wallis test followed
by Dunn’s post-hoc test (comparison between three groups).
Statistical significance for these tests was set at 0.05 (2-tailed tests).
The stage, the presence of the parasite in CSF and the severity of
neurological signs were successively considered as the dependent
variables. The different marker concentrations were considered as
independent variables. Bivariate non-parametric correlations using
the Spearman correlation coefficient were carried out with
statistical significance set at 0.01 (2-tailed tests).
To calculate the sensitivity and specificity of each individual
predictor with respect to staging, the specific receiver operator
characteristic (ROC) curve of each analyte was determined and
the cutoff value was selected as the threshold predicting stage 2
patients with 100% of specificity (Figure S1).
Aabel (version 2.4.2, Gigawiz Ltd. Co., Tulsa, OK, USA) was
used for box plots, SPSS for scatter plots and R (version 2.8.0) [29]
was used for plotting ROC curves.
Panel development
Panel selection was mainly performed as described by Reynolds
et al. [30]. Briefly, the optimized cutoff values were obtained by
modified iterative permutation-response calculations (rule-induc-
tion-like, RIL) using only the molecules that presented a p
value,0.0001 (Mann-Whitney U test), an AUC above 75% and a
significant Spearman correlation with WBC above 0.4 (Table 2).
Each cutoff value was changed iteratively by quantile of 2%
increment and sensitivity was determined after each iteration until
a maximum sensitivity was achieved for 100% specificity. The
permutation–response calculations were conducted using a PERL
program (ActivePerl version 5.10.0.1004, ActiveState Software
Inc.) and data were coded in CSV format.
Results
Biomarker concentration as a function of disease stage
The main characteristics of the 100 patients evaluated in this
study are presented in Table 1. The analytes were classified into
Biomarkers for Staging HAT
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for the classification were the significance (Mann-Whitney U test),
the AUC and the correlation with WBC. In the first group (GR1)
comprising IL-1ra, G-CSF, CCL4, and VEGF, no significant
difference in CSF concentrations between the two stages of HAT
was observed. The second group (GR2) encompassed IFN-c, IL-9,
CCL2 and S100b, for which concentrations in the CSF were
significantly different between stage 1 and stage 2 patients
(0.001,p,0.01, Mann-Whitney U test). The third group (GR3)
included GSTP-1, H-FABP, TNF-a, IL-1b, IL-6, IL-10, CXCL8
and CXCL10, for which the difference between stages was highly
significant (p,0.0001, Mann-Whitney U test) (Figure S2).
To assess the sensitivity and specificity of these analytes for S2
HAT, ROC curves were built. GR1 and GR2 had a low to
medium area under ROC curve (AUC) ranging from 54 to 70%
and also displayed a low sensitivity in detecting S2 patients (4–13%
for GR1 and 10–44% for GR2, see Table 2) at a predefined
specificity of 100%. GR3 showed higher AUC (79–95%), and
sensitivities for identification of S2 patient up to 84% (Table 2).
CXCL10 appeared then as the most accurate predictor for
staging, as, with a cutoff set at 2080 pg/mL, this molecule
identified 66 out of 79 late stage patients and ruled-out all the
early-stage patients.
Correlation between WBC and biomarker concentrations
As the white blood cell count was one of the two reference staging
parameters, we investigated the correlation between the concen-
trations of the sixteen biomarkers and the number of WBC in CSF
(Table 2). There was no significant correlation in the concentrations
ofthe firstand secondgroupofanalytes(GR1 and GR2) with WBC,
except for S100b, which had a significant but low Spearman rho
coefficient (0.269, p,0.01). Otherwise, strong correlations were
observed between WBC and the concentrations of GR3 biomarkers
(GSTP-1, IL-1b, IL-6, H-FABP, TNF-a, IL-10, CXCL8 and
CXCL10),withSpearmanrhorangingfrom0.417to0.732(Table2
and Figure 1). The levels of GR3 molecules in 8 potential
intermediate stage patients (parasite not detected in CSF and
having .5a n d#20 WBC/mL) demonstrated the intermediate
behaviour of this category with some patients appearing as S1 and
others as S2 patients (Figure 1). Based on the above results, only the
GR3 molecules (GSTP-1, IL-1b, IL-6, H-FABP, TNF-a, IL-10,
CXCL8 and CXCL10) were selected for further analyses.
Table 1. Characteristics of the studied population.
Stage 1 Stage 2
Population n 21 79
Gender Male 8 51
Female 13 28
Age Median (range) 32.0 (14–60) 33.0 (13–65)
WBC/ml Median (range) 2 (0–5) 126 (6–6304)
Parasite in CSF N 0 64
Neurological signs* Absence 11 11
Moderate 10 51
Severe 0 15
.5a n d#20 WBCmLN o
trypanosomes in CSF**
N0 8
*Neurological signs were not reported for two patients.
**Correspond to the number of patients highlighted as being in the potential
intermediate stage.
doi:10.1371/journal.pntd.0000459.t001
Table 2. Detailed results for all the molecules tested in respect with the stage of the disease.
Absence of parasite
and #5 WBC/ml
Presence of parasite
and/or .5 WBC/ml
Mann-Whitney U
test
Correlation with
WBC
ROC
curve
Markers Median (range) Median (range) p value (spearman rho) % AUC
Cutoff
[pg/mL]
Sensitivity,
% (95% CI)
a
GR3 CXCL10 347.3 (24.3–2048.8) 14130.0 (24.3–128900.0) ,0.0001 0.625** 95 .2080.0 84 (74–91)
CXCL8 56.9 (1.3–96.5) 178.9 (1.6–1791.0) ,0.0001 0.557** 94 .97.1 82 (72–90)
IL-10 6.7 (0.9–19.6) 74.5 (2.1–573.1) ,0.0001 0.702** 89 .20.0 80 (69–88)
TNF-a 3.3 (0.5–8.4) 22.5 (1.0–295.4) ,0.0001 0.636** 93 .8.5 78 (68–87)
H-FABP 226.4 (19.8–564.0) 748.3 (0.0–16680.0) ,0.0001 0.417** 86 .571.8 62 (50–73)
IL-6 5.0 (0.2–57.7) 63.8 (0.8–3286.0) ,0.0001 0.732** 94 .58.0 52 (40–63)
IL-1b 0.1 (0.1–0.7) 0.6 (0.1–42.2) ,0.0001 0.445** 80 .0.7 48 (37–60)
GSTP-1 1272.9 (149.7–5026.9) 3014.0 (61.2–75810.0) ,0.0001 0.437** 79 .5078.0 24 (15–35)
GR2 IFN-c 68.7 (8.6–209.2) 100.4 (1.7–995.5) 0.0049 0.094 70 .210.9 10 (4–19)
IL-9 23.4 (3.6–44.5) 30.7 (3.6–209.6) 0.0051 0.041 70 .45.0 23 (14–34)
S100b 43.2 (4.9–113.0) 78.4 (0.0–353.0) 0.0053 0.269** 70 .114.3 29 (19–40)
CCL2 428.1 (58.6–632.9) 590.2 (15.8–5391.0) 0.0055 0.156 70 .664.7 44 (33–56)
GR1 G-CSF 43.4 (2.4–209.8) 63.2 (2.0–785.9) 0.0866 (ns) 20.029 62 .281.7 4 (1–11)
IL-1ra 817.3 (128.6–3087.6) 782.0 (34.0–11760.0) 0.5229 (ns) 20.065 55 .3092.0 13 (6–22)
CCL4 94.2 (1.5–301.0) 91.9 (5.4–753.9) 0.5423 (ns) 20.143 54 .316.6 5 (1–12)
VEGF 48.3 (20.0–215.7) 49.4 (3.5–1009.0) 0.9393 (ns) 20.105 54 .222.4 9 (4–17)
aSensitivity was set for a specificity of 100% (95% CI, 84–100).
**Correlation is significant at the 0.01 level (2-tailed).
doi:10.1371/journal.pntd.0000459.t002
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GR3 molecule concentrations were classified according to the
absence/presence of trypanosomes in CSF. GSTP-1, IL-1b,I L -
6, H-FABP, TNF-a, IL-10, CXCL8 and CXCL10 concentra-
tions were significantly increased in patients with parasites in
CSF (Figure 2 and Table S1). The six biomarkers associated
with inflammation had a lower p value (,0.0001, Mann-
Whitney U test) and higher AUC (ranging from 78% to 89%)
than H-FABP and GSTP-1 (0.001,p,0.05, Mann-Whitney U
test, AUCs of 69% and 64% respectively). Additionally, when
only S2 patients were analysed, CXCL10, IL-10 and TNF-a
levels still demonstrated a significant difference between patients
with or without trypanosomes in CSF (p,0.05, Dunn’s post-hoc
test, Table S1).
Neurological signs and biomarker concentrations
The patients were classified with respect to the neurological
signs reported (absence, moderate or severe) (Figure 3). All the
GR3 molecules except GSTP-1 showed a significant increase in
concentration associated with higher severity of neurological signs
(p,0.05, Kruskal-Wallis test). Indeed, CXCL10, CXCL8, IL-6,
IL-10, IL-1b, and TNF-a concentrations were significantly
different between patients without neurological signs and severe
neurological signs (p,0.05, Dunn’s post-hoc test), as well as
between patients with moderate and severe neurological signs
(p,0.05, Dunn’s post-hoc test). H-FABP level was significantly
different between patients without neurological signs and severe
neurological signs (p,0.05, Dunn’s post-hoc test). Only the
concentrations of CXCL10, IL-10 and TNF-a could distinguish
Figure 1. Scatter plots correlating the level of GR3 molecules with the WBC count. The horizontal dashed line corresponds to the cutoff
value for the molecule that discriminates between S1 and S2 patients with a specificity of 100%. The left vertical dashed line corresponds to the WBC
count cutoff value used for staging. The second vertical dashed line indicates the suggested cutoff value for staging. Patients between these lines
(.5 and #20 WBC/mL) corresponded to potential intermediate stage patients. The diagonal line corresponds to the linear regression.
doi:10.1371/journal.pntd.0000459.g001
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www.plosntds.org 5 June 2009 | Volume 3 | Issue 6 | e459between absence and moderate neurological signs (p,0.05,
Dunn’s post-hoc test).
Panel selection
In an effort to improve the global sensitivity of molecules in the
prediction of second stage HAT, the GR3 molecules were
combined using the rule induction like (RIL) approach. This
resulted in the identification of a three-molecule panel character-
ized by CXCL10, CXCL8 and H-FABP (cutoff values were set at
2080.0, 97.1 and 571.8 pg/mL, respectively). A positive test
(leading to identification of S2 patient) was obtained as soon as one
of the three molecules included in the panel was above its cutoff
value (Table 3). The panel had a sensitivity of 97% (95% CI, 91–
100%) and, by definition, a specificity of 100% (95% CI, 84–
100%). This means that the panel could identify 77 out of 79 stage
2 patients, and ruled-out all the 21 stage 1 patients. Out off the 77
ruled-in S2 patients, 5 were CXCL10 positive only (.2080.0 pg/
mL), 6 CXCL8 positive only (.97.1 pg/mL) and 3 H-FABP
positive only (.571.8 pg/mL). The rest of ruled-in S2 patients
were identified with either 2 positive molecules (n=23) or 3
positive molecules (n=40). When this panel was applied on the
intermediate stage patients (eight patients having .5 and #20
WBC/mL and no trypanosomes in CSF) only one patient gave a
negative test response and thus 7 out of 8 patients were classified as
S2.
Discussion
In this study, including early and late stage HAT patients
(n=100), we evaluated sixteen molecules as potential staging
markers of HAT, to replace or complement trypanosome
Figure 2. Box-plot of GR3 molecules and WBC classified according to the presence of the parasite in CSF. Median and mean are
represented as a solid line in the box and a diamond respectively. Whisks are defined as 5
th–95
th percentile without outliers. Half-width of the notch
was calculated automatically by the software.
doi:10.1371/journal.pntd.0000459.g002
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www.plosntds.org 6 June 2009 | Volume 3 | Issue 6 | e459Figure 3. Box-plot of GR3 molecules and WBC classified according to the neurological signs. Median and mean are represented as a solid
line in the box and a diamond respectively. Whisks are defined as 5
th–95
th percentile without outliers. Half-width of the notch was calculated
automatically by the software. Neurological signs of two patients were not reported (n=98).
doi:10.1371/journal.pntd.0000459.g003
Table 3. Detailed results for the three molecule panel in respect with the stage of the disease.
Markers
Number of
negative test
Number of
positive test
Mann-Whitney U
test , p value
% AUC
(ROC curve) Panel cutoff
Sensitivity, %
(95% CI)
a
Panel CXCL10, CXCL8, H-FABP 23 77 ,0.0001 99 $1 molecule above its
cutoff value
b
97 (91–100)
aSensitivity was set for a specificity of 100% (95% CI, 84–100).
bCutoff values: CXCL10.2080.0 pg/mL, CXCL8.97.1 pg/mL and H-FABP.571.8 pg/mL.
doi:10.1371/journal.pntd.0000459.t003
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CXCL8, IL-6, IL-10, IL-1b, TNF-a, H-FABP and GSTP-1,
presented concentrations significantly elevated in the CSF of late-
stage HAT patients. We demonstrated that the CSF concentration
of CXCL10 is highly elevated in stage 2 patients when compared
to stage 1, highlighting this molecule as a potential new staging
marker for sleeping sickness. A combinatorial approach has been
applied in staging of HAT, in order to improve the sensitivity. This
method has led to the identification of a panel consisting of
CXCL10, CXCL8 and H-FABP, that identified late-stage patients
with a sensitivity of 97% at 100% specificity.
H-FABP is a small protein belonging to the fatty acid-binding
proteins (FABPs) and known to be expressed in the brain [31]. In
myocardial infarction, HFABP is quickly released after the tissue
damage [32,33]. It has been suggested that the release of H-FABP
from damaged cells could be used for diagnosis of acute and
chronic brain injuries [31]. GSTP-1 is a member of the
Glutathione S-transferase superfamily, playing a role in oxidative
stress. Its expression in brain has not been well studied, but GSTP-
1 seems to be the main isoform in brain [34] and may function as a
brain damage biomarker [24]. Our results showed a higher level of
both H-FABP and GSTP-1 in CSF of late stage patients compared
to early stage patients. These two molecules are known to be
associated with early brain cell death [24,31], which could be
correlated with the observed increase of their concentration in
late-stage HAT patients. From now, it is not know if these two
molecules were also associated with the inflammatory process.
Cytokines and chemokines play an important role in inflam-
matory processes and blood-brain barrier (BBB) dysfunction [35],
and could therefore be potentially used as markers for staging
HAT [11,16,36]. In the present study, the measured levels of
inflammation-related proteins in CSF showed significant differ-
ences according to the disease progression. Indeed, concentrations
of IL-1b, IL-6, IL-10, TNF-a, CXCL8 and CXCL10 were
increased in the CSF of patients in late stage HAT compared to
those in early stage of the disease. In addition, the levels of IL-1b,
IL-6, CXCL8 and IL-10 were similar to those already reported for
T. b. gambiense HAT [11,16]. IL-1b is a pro-inflammatory cytokine
that induces leukocytes infiltration [37] and is rapidly expressed in
response to brain damage [35]. The high level of IL-1b found in
CSF of stage 2 patients confirmed its probable association with the
inflammatory process. Furthermore, its level was clearly correlated
to the presence of severe neurological signs, supporting a potential
release in relation to neurodegeneration. IL-6 and IL-10 are both
anti-inflammatory cytokines. Their increased level in the CSF
according to the stage as well as the severity of the neurological
signs confirmed their activation associated with disease progres-
sion. The concentration of the two molecules was significantly
increased in patients with more than 20 WBC/mL, which may
suggest a probable expression after an already activated inflam-
matory process. Indeed, it has been demonstrated in vervet
monkey models of HAT that IL-10 is associated with down-
regulation of pro-inflammatory cytokines (IFN-c and TNF-a)i n
the late stage of T. b. rhodesiense disease [38]. The level of the pro-
inflammatory chemokine CXCL8 was also significantly elevated in
CSF of S2 patients and correlated well with both presence of
trypanosomes in CSF and severity of neurological signs. CXCL8 is
a strong neutrophil attractant [16], which could thus not explain
the good correlation of CXCL8 and the number of WBC (mainly
B-lymphocytes) in CSF. However, its elevation in patients with a
relatively low number of WBC (between 5 and 20/mL) suggests an
early activation, which may play a role in BBB dysregulation [11].
The pro-inflammatory cytokine TNF-a has been reported as
being involved in blood-brain barrier dysfunction [39]. These
authors also demonstrated that trypanosomes may induce synthesis
of TNF-a. In the present study, the increasing level of TNF-a was
associated with disease progression as well as the presence of the
parasite in CSF. These results suggested that parasites invasion into
theCNSmayleadtoTNF-aproduction,whichgeneratedthenCNS
inflammation [14]. Additionally, an elevation according to the
severity of the neurological symptoms was observed, which may
support the neurotoxic effect of this cytokine in HAT [35].
CXCL10, also known as IP-10, is a pro-inflammatory chemokine
with a central role in inflammatory responses [40]. The main effect
of CXCL10 as a chemotactic molecule is activation of T cell
migration to the site of inflammation, after binding to its receptor,
CXCR3 [41]. The involvement of this chemokine in different CNS
disorders has been demonstrated, such as viral meningitis [42] and
multiple sclerosis [43], where increased CXCL10 levels in the CSF
correlatedwithtissueinfiltrationofTlymphocytes[44].Inourstudy,
the concentration of CXCL10 increased with progression of the
disease, and was highly correlated with the number of WBC in CSF.
Many studies have pointed out astrocytes as the primary source of
CXCL10 at the level of the CNS and showed that this molecule is
responsible, as chemoattractant, for the influx of activated T
lymphocytes inbrain[43,45–47].Indeed,thereisa predominanceof
plasma cell infiltration in the brain of trypanosomiasis infected
individuals. In addition, it has very recently been shown in a mouse
model of HAT that CXCL10 may play an important role in T-cell
recruitment into the brain parenchyma and is probably associated
with brain invasion by trypanosomes [48]. Furthermore, the early
activation of cytokine production (TNF-a, IL-6, and IFN-c)b y
astrocytes and microglia inmicemodelsinfected with T.bruceibefore
observation of an inflammatory response [49] has confirmed an
important role of astrocyte activation in CNS inflammatory
response. In consequence, early astrocyte activation, which induces
CXCL10 production, is probably linked with BBB dysfunction and
may occur before the inflammatory process. These hypotheses were
supported by the increase CXCL10 concentration observed in
patients having .5a n d#20 WBC/mL but without trypanosomes
detected in the CSF. The CXCL10 level was also demonstrated to
be elevated in patients with cerebral malaria, and pointed out as
potentially inducing apoptosis of endothelial cells leading to BBB
breakdown [17] Recent work has suggested that neuronal apoptosis
associated with calcium dysregulation may be induced by CXCL10
[50]. Even if mechanisms of CXCL10 mediated neurotoxicity
remain unclear, we showed that the concentration of CXCL10 was
correlated to the severity of neurological signs, supporting a possible
involvement of this protein in neuronal injury pathways. Thus,
CXCL10 expression in late stage HAT patients may be associated
with both cell death and inflammatory process. Finally, active
tuberculosis and pregnancy, two exclusion criteria in this study, have
also been reported as modulating the level of CXCL10 [51,52].
Although they have only been evaluated on serum and whole blood
samples so far, it is not excluded that these criteria could potentially
induce CXCL10 modulation in CSF. Nevertheless, our data
demonstrated that CXCL10 is an efficient tool for staging patients,
and suggested a potential role of CXCL10 as an early marker of
parasite invasion into the CNS.
As the investigated proteins may be involved in different
biological mechanisms, we evaluated in this study a strategy to
combine results of each molecule, in order to find a panel able to
discriminate more accurately early and late stage patients. This
highlighted a panel of three molecules, including CXCL10 (the
most promising single molecule), CXCL8 (another chemokine)
and H-FABP (a marker of brain damage). With a specificity of
100%, this panel increased the sensitivity for staging of HAT
patients up to 97% (compared to the 84% obtained with CXCL10
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patients was small, the panel appeared to classify them rather as
S2 patients (7/8 patients). This supports the current recommen-
dation by WHO to consider such patients as S2 patients and treat
them with drugs used for late stage disease. However, there is a
need for more studies on T. b. gambiense and T. b. rhodesiense
patients, before and after treatment, as well as on other parasitic
diseases such as cerebral malaria, to verify these results and assess
the feasibility of using the three-molecule panel as a complement
to WBC count. There are obviously some drawbacks concerning
this approach. Firstly the obtained panel is not 100% sensitive and
thus some stage 2 patients will not be detected. The influence of
other possible co-infections should also be evaluated in order to
determine if they significantly modulate the evaluated molecules.
Indeed, the three molecules included in the panel could potentially
all be markers of other CNS disorders. It is also evident that the
methods described in this study could not be implemented in such
a way directly in the field and should be first transformed into a
more simplified technique as for example a lateral flow
immunoassay. Another limitation is the continued requirement
of the invasive lumbar puncture since the molecules highlighted in
this study have been evaluated on CSF samples.
In conclusion, the present study demonstrated the utility of
inflammation-related proteins and brain damage markers as
indicators of the second stage of HAT but potentially in other
CNS disorders as well. We highlighted the value of CXCL10 as an
efficient staging biomarker for T. b. gambiense infected HAT
patients. Additionally, a combination of CXCL10 with CXCL8
and H-FABP resulted in a highly sensitive tool for identification of
late stage HAT patients.
Supporting Information
Figure S1 ROC curves of GR3 molecules and the panel. *Cut-
off value for each molecule [pg/ml] and for the panel is displayed
by a point and the numeric value. In parenthesis, sensitivity (%) of
each molecule was set for 100% specificity. Area under the ROC
curve (AUC) is also given.
Found at: doi:10.1371/journal.pntd.0000459.s001 (1.37 MB TIF)
Figure S2 Box-plot of GR3 molecules classified according to the
stage of the disease. *Median and mean are represented as a solid
line in the box and a diamond respectively. Whisks are defined as
5th–95th percentile without outliers. Half-width of the notch was
calculated automatically by the software.
Found at: doi:10.1371/journal.pntd.0000459.s002 (0.69 MB TIF)
Table S1 Detailed results for GR3 molecules in function of the
presence of trypanosomes in CSF (according or not to the stage)
and the neurological signs.
Found at: doi:10.1371/journal.pntd.0000459.s003 (0.01 MB
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